Alkermes plc. Net Cash Provided by (Used in) Continuing Operations
Alkermes plc. (ALKS) reported Net Cash Provided by (Used in) Continuing Operations of -$42.95 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-25.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2016-02-25
- Alkermes plc. net cash provided by (used in) continuing operations for the quarter ending 2015-03-31 was -$14.75M.
- Alkermes plc. net cash provided by (used in) continuing operations for the quarter ending 2014-12-31 was $87.88M.
- Alkermes plc. net cash provided by (used in) continuing operations for the quarter ending 2014-09-30 was -$52.14M, a 191.30% decline year-over-year.
- Alkermes plc. net cash provided by (used in) continuing operations for the quarter ending 2014-06-30 was $32.00M, a 64.63% increase year-over-year.
- Alkermes plc. net cash provided by (used in) continuing operations for fiscal 2015 was -$42.95M, a 176.02% decline from fiscal 2014.
- Alkermes plc. net cash provided by (used in) continuing operations for fiscal 2014 was $56.50M, a 78.41% increase from fiscal 2013.
- Alkermes plc. net cash provided by (used in) continuing operations for fiscal 2013 was $31.67M.
- Alkermes plc. net cash provided by (used in) continuing operations for fiscal 2013 was $13.36M, a 70.45% decline from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2015-12-31 | -$42.95M 10-K · filed 2016-02-25 | |||
| 2015-03-31 | -$14.75M 10-Q · filed 2015-04-30 | $73.13M derived: sum of 2 quarters · filed 2016-02-25 | $20.99M derived: sum of 3 quarters · filed 2016-02-25 | $52.99M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-12-31 | $87.88M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $35.74M derived: sum of 2 quarters · filed 2016-02-25 | $67.74M derived: sum of 3 quarters · filed 2016-02-25 | $56.50M 10-K · filed 2016-02-25 |
| 2014-09-30 | -$52.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | -$20.14M derived: sum of 2 quarters · filed 2014-10-29 | -$31.38M 10-Q · filed 2014-10-29 | -$37.32M derived: sum of 4 quarters · filed 2015-04-30 |
| 2014-06-30 | $32.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $20.76M 10-Q · filed 2014-07-31 | $14.82M derived: sum of 3 quarters · filed 2015-04-30 | $71.92M derived: sum of 4 quarters · filed 2015-04-30 |
| 2014-03-31 | -$11.24M 10-Q · filed 2015-04-30 | -$17.18M derived: sum of 2 quarters · filed 2015-04-30 | $39.93M derived: sum of 3 quarters · filed 2015-04-30 | $59.36M derived: sum of 4 quarters · filed 2015-04-30 |
| 2013-12-31 | -$5.94M derived: 10-K 9 month − 10-Q 6 month · filed 2015-02-24 | $51.16M derived: sum of 2 quarters · filed 2015-02-24 | $70.60M 10-K · filed 2015-02-24 | $31.67M 10-K · filed 2016-02-25 |
| 2013-09-30 | $57.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $76.54M 10-Q · filed 2013-10-31 | $37.61M 10-Q · filed 2014-10-29 | $41.09M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $19.44M 10-Q · filed 2013-07-25 | -$19.50M 10-Q · filed 2014-07-31 | -$16.02M derived: sum of 3 quarters · filed 2015-02-24 | $30.80M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | -$38.93M 10-Q · filed 2014-04-30 | -$35.46M derived: sum of 2 quarters · filed 2015-02-24 | $11.36M derived: sum of 3 quarters · filed 2015-02-24 | $13.36M 10-K · filed 2015-02-24 |
| 2012-12-31 | $3.47M derived: 10-K 9 month − 10-Q 6 month · filed 2015-02-24 | $50.29M derived: sum of 2 quarters · filed 2015-02-24 | $52.29M 10-K · filed 2015-02-24 | $50.56M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-09-30 | $46.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-10-31 | $48.82M 10-Q · filed 2013-10-31 | $47.09M derived: sum of 3 quarters · filed 2014-02-27 | $43.18M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $2.00M 10-Q · filed 2013-07-25 | $268.00K derived: sum of 2 quarters · filed 2014-02-27 | -$3.64M derived: sum of 3 quarters · filed 2014-02-27 | $49.65M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$1.73M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | -$5.64M derived: sum of 2 quarters · filed 2014-02-27 | $47.65M derived: sum of 3 quarters · filed 2014-02-27 | $45.21M 10-KT · filed 2014-02-27 |
| 2011-12-31 | -$3.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $49.38M derived: sum of 2 quarters · filed 2013-01-31 | $46.94M 10-Q · filed 2013-01-31 | |
| 2011-09-30 | $53.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-01 | $50.84M 10-Q · filed 2012-11-01 | ||
| 2011-06-30 | -$2.45M 10-Q · filed 2012-07-26 | |||
| 2011-03-31 | -$40.93M 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |